Skip to main content

Table 5 Modification of the sweat test and the NPD results after gentamicin treatment.

From: In vitroprediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study

 

Group A

n = 9

Group B

n = 4

Group C

n = 5

Patients

D0

D15

p

D0

D15

p

D0

D15

p

Sweat chloride (mM/L)

109(17)

85(31)

0.03

110(7)

112(16)

NS

96(1.5)

105(18)

NS

Basal PD

-56(10)

-49(5)

0.12

-53(11)

-50(8)

NS

-52(8)

-52(7)

NS

ΔAmiloride

20(6)

15(7)

0.09

22(15)

20(9)

NS

19(12)

21(13)

NS

ΔCl-free-isoproterenol

-0.8(1.3)

-4.6(6)

0.04

-0.2(0.5)

-0.9(1)

NS

0(0.5)

-0.8(1)

NS

  1. Group A: patients with the Y122X stop mutation. Group B: patients with another stop mutation. Group C: patients without any stop mutation. Data are described as mean (SD). Comparison with Wilcoxon test.